NBTX Stock Analysis: Buy, Sell, or Hold?
NBTX - Nanobiotix S.A. American Depositary Shares
$34.07
3.20 (10.37%)
▲
5d:
+11.23%
30d:
+11.41%
90d:
+57.22%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: Apr 01, 2026
0d
Get Alerted When NBTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NBTX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: NBTX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NBTX is currently trading at $34.07, which is considered slightly high relative to its 30-day fair value range of $28.18 to $34.96. From a valuation perspective, the stock is trading at a discount (Forward PE: -84.3) compared to its historical average (80.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NBTX is in a strong uptrend. The price is approaching resistance at $34.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $27.43. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NBTX is in a strong uptrend. The price is approaching resistance at $34.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $27.43. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$28.18 -
$34.96
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.4%)
- BEARISH: Trading 19.5% above Wall St target ($27.43)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Fair Price Analysis
30-Day Fair Range
$28.18 -
$34.96
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$28.40
Resistance Level
$34.27
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-84.35
Wall Street Target
$27.43
(-19.5%)
Revenue Growth (YoY)
186.8%
PE vs Historical
-84.4 vs 80.3
CHEAP
Share & Embed Analysis
Last updated: April 01, 2026 6:25 PM ET
Data refreshes hourly during market hours. Next update: 7:25 PM
Data refreshes hourly during market hours. Next update: 7:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 55 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$132 | 56 HOLD |
